Liquidia Corporation Common Stock vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Liquidia Corporation Common Stock trades at $34.11 (market cap $3.04B), while Direxion Daily S&P 500 Bull 3X Shares trades at $284.84 (market cap $7.34B). The key difference: Direxion Daily S&P 500 Bull 3X Shares is far larger — about 2.4× Liquidia Corporation Common Stock's market cap, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Direxion Daily S&P 500 Bull 3X Shares for 33 Days on average.
| LQDA | SPXL | |
|---|---|---|
Market Cap | $3.04B | $7.34B |
Volume | 21,111,778 | 2,272,949 |
Sector | Health | Leveraged / Inverse |
52-Week High | $91.03 | $301.38 |
52-Week Low | $22.02 | $170.20 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $2.94B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPXL trades at $297.37 with no daily change, maintaining a bullish technical stance supported by moving averages. The ETF shows neutral oscillator signals with RSI at 75.74 suggesting potential overbought conditions. Recent news highlights S&P 500 valuation concerns amid strong profit growth expectations of 35% for 2026, though projections slow to 15% for 2027 according to Wall Street analysts.
The ETF's outlook remains tied to S&P 500 performance, with seasonal patterns and earnings growth as key catalysts. Risks include market concentration in top holdings and geopolitical uncertainty. Analyst sentiment is mixed with technical indicators favoring upside while fundamental valuations warrant caution given projected earnings deceleration.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →